A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study]
2020-07-04
عنوان الدراسة
A PHASE III PROSPECTIVE, TWO-COHORT NON-RANDOMIZED, MULTI-CENTRE, MULTINATIONAL, OPEN LABEL STUDY TO ASSESS THE SAFETY OF ASSISTED- AND SELF-ADMINISTERED SUBCUTANEOUS TRASTUZUMAB AS THERAPY IN PATIENTS WITH OPERABLE HER2-POSITIVE EARLY BREAST CANCER [SafeHer Study]
داعم الدراسة
Roche
دواء الدراسة
trastuzumab
رقم بروتوكول الدراسة
MO28048
حالة الدراسة
Ongoing
موقع الدراسة
King Faisal Specialist Hospital and Research Center (Jeddah), King Abdulaziz Medical City NG (Riyadh)
مرحلة الدراسة
3
التعليقات والاقتراحات
لأي استفسارات أو ملاحظات حول الخدمات الحكومية، يرجى تعبئة المعلومات المطلوبة.